Shannon Dahl

Dr. Dahl was a co-founder and VP of Technology at Humacyte, where she led the development of engineered vascular grafts for dialysis patients, worked based on her studies at Duke University. Prior to Duke, Dr. Dahl graduated from the Massachusetts Institute of Technology. While at Humacyte, she led the company's efforts that resulted in award of the first Regenerative Medicine Advanced Therapy (RMAT) designation for Humacyte's development candidate. Dr. Dahl currently serves as the CSO Cell Care Therapeutics.